55P Time to combine? A predictive modeling study of combination systemic therapies in patients with salivary gland cancers based on phase II clinical trials

ESMO rare cancers. 2026 Open access

Read full text
Authors: J. Sanz Beltran, Pablo Jiménez-Labaig, C. Ogles, M. Forster, P. Bossi, Robert Lewin Metcalf, Irene Braña, G.J. Hanna, Santiago Cabezas-Camarero, K.J. Harrington
DOI: 10.1016/j.esmorc.2026.100261
Cited by: 0

Abstract

Salivary gland cancers are rare, heterogeneous tumors with limited systemic options for recurrent or metastatic disease. Chemotherapy, androgen-targeted and anti-HER2 agents have shown activity as monotherapies, but their combined effect remains unknown in tumors expressing androgen receptor (AR), with or without HER2 positivity. Using statistical additivity models and the TRIPOD guidelines, drug-combination predictions were performed to support future clinical trial designs.

Fields of Study & Subjects

Salivary Gland Tumors Diagnosis and Treatment Salivary Gland Disorders and Functions Breast Cancer Treatment Studies

Publication details

Journal / source
ESMO rare cancers.
Volume
5
Pages
100261–100261
Publication date
1 March 2026
Language
EN